



February 07, 2019

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Sub : **Disclosure of the Outcome of the Board Meeting under Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Ref : **HealthCare Global Enterprises Limited (“the Company”)**
(NSE Scrip Code: HCG/ BSE Scrip Code: 539787)

Dear Sir/Madam,

We wish to inform you that the Board of Directors of the Company (“Board”), at their meeting held on this day, the 7th February 2019, *inter alia*, has considered and approved the following agenda:

1. Unaudited Standalone and Consolidated Financial Results of the Company (Limited Review), for the quarter and nine months ended December 31, 2018 and
2. Issue and allotment of 30,750 (Thirty Thousand Seven Hundred Fifty Only) equity shares of the Company, upon exercise of Employee Stock Options under Employee Stock Option Scheme, 2014 of the Company.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Unaudited Standalone and Consolidated Financial Results of the Company (Limited Review) along with the Limited Review Reports for the quarter and nine months ended December 31, 2018;

The Meeting of the Board concluded at 04.30 P.M.

Request you to take this on record.

For HealthCare Global Enterprises Limited

Sunu Manuel
Company Secretary & Compliance Officer

Encl: as above

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489

B S R & Co. LLP

Chartered Accountants

Maruthi Info-Tech Centre
11-12/1 Inner Ring Road
Koramangala
Bangalore 560 071 India

Telephone +91 80 7134 7000
Fax +91 80 7134 7999

Limited review report on unaudited quarterly standalone financial results and standalone year-to-date results of HealthCare Global Enterprises Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of HealthCare Global Enterprises Limited

We have reviewed the accompanying statement of unaudited standalone financial results ('Statement') of HealthCare Global Enterprises Limited ('the Company') for the quarter ended 31 December 2018 and the year-to-date results for the period from 1 April 2018 to 31 December 2018 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* specified under section 143(10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

for B S R & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022



Amit Somani
Partner
Membership No. 060154

Place: Bengaluru
Date: 7 February 2019

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2018

(Rs. in Lakhs except share data)

Sl. No.	Particulars	3 months ended 31 December 2018	Preceding 3 months ended 30 September 2018	Corresponding 3 months ended in the previous year 31 December 2017	Year to date figures for the current period ended 31 December 2018	Year to date figures for the previous period ended 31 December 2017	Previous year ended 31 March 2018
		Unaudited	Unaudited	Unaudited (Refer note 4)	Unaudited	Unaudited (Refer note 4)	Audited
1	Income						
	(a) Revenue from operations	15,936	16,152	14,681	47,489	43,425	58,627
	(b) Income from government grant	31	15	-	61	-	60
	(c) Other income	124	280	849	574	1,224	1,593
	Total income	16,091	16,447	15,530	48,124	44,649	60,280
2	Expenses						
	(a) Purchases of medical and non-medical items	3,682	4,005	4,066	11,580	12,250	15,782
	(b) Changes in inventories	106	(144)	(164)	(56)	(569)	(267)
	(c) Employee benefits expense	3,360	3,198	2,987	9,589	8,693	11,559
	(d) Finance costs	1,197	1,444	792	3,615	1,899	2,680
	(e) Depreciation and amortisation expense	1,217	1,172	1,112	3,453	3,228	4,392
	(f) Medical consultancy charges	3,190	2,919	3,004	8,923	8,307	10,340
	(g) Other expenses	3,374	3,686	2,470	10,373	8,356	12,400
	Total expenses	16,126	16,280	14,267	47,477	42,164	56,886
3	Profit/(loss) before exceptional items and tax (1-2)	(35)	167	1,263	647	2,485	3,394
4	Exceptional items [refer note 3]	-	-	-	-	-	294
5	Profit/(loss) before tax (3+4)	(35)	167	1,263	647	2,485	3,688
6	Tax expense						
	- Current tax	-	36	300	154	616	863
	- Deferred tax	(17)	22	144	71	244	335
	Total tax expense	(17)	58	444	225	860	1,198
7	Profit/ (loss) for the period / year (5-6)	(18)	109	819	422	1,625	2,490
8	Other comprehensive income / expense						
	(i) Items that will not be reclassified subsequently to profit or loss						
	- Remeasurements of the defined benefit plans	-	-	-	-	-	(30)
	- Income tax effect on above	-	-	-	-	-	10
	(ii) Items that will be reclassified to profit or loss						
	- Effective portion of loss on hedging instruments in a cash flow hedge	(219)	(400)	29	(619)	-	-
	- Income tax on (ii) above	75	140	(10)	215	-	-
	Other comprehensive income/expense for the period / year, net of tax	(144)	(260)	19	(404)	-	(20)
9	Total comprehensive income/(loss) for the period / year (7+8)	(162)	(151)	838	18	1,625	2,470
10	Paid-up equity share capital (Face value of Rs. 10 each)	8,789	8,786	8,688	8,789	8,571	8,690
11	Reserves, i.e., 'Other equity'						52,156
12	Earnings/(loss) per equity share (face value of Rs. 10 each)	Not annualised	Not annualised	Not annualised	Not annualised	Not annualised	Annualised
	(a) Basic	(0.02)	0.12	0.96	0.48	1.90	2.89
	(b) Diluted	(0.02)	0.12	0.95	0.48	1.90	2.89
	See accompanying notes to the Standalone Financial Results						



STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2018

Notes:

- 1 The statement of unaudited standalone financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company') for the quarter and nine months ended 31 December 2018 has been reviewed by the Audit and Risk Management Committee and approved by the Board of Directors at their meeting held on 7 February 2019. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.

The Statement has been subjected to limited review by the statutory auditor of the Company. The review report of the auditor is unqualified.

- 2 The statement of category wise utilisation of net proceeds from Initial Public Offer is:

Category wise utilisation of net proceeds from Initial Public Offer	Amount proposed to be utilised	(Rs. in Lakhs)
		Actual utilisation upto 31 December 2018
Purchase of medical equipment	4,220	-
Investment in IT software, services and hardware	3,019	1,627
Pre-payment of debt	14,704	14,700
General corporate purposes	1,977	1,977
Total	23,920	18,304

Details of unutilised funds as on 31 December 2018		(Rs. in Lakhs)
Investment in fixed deposits		1,077
Amount parked in cash credit account		4,539
Total		5,616

- 3 Exceptional items:

- a During the year ended 31 March 2018, the Company has entered into a business transfer agreement with Strand Life Sciences Private Limited ('Strand') dated 2 January 2018 for sale of its Triesta unit on slump sale basis for a lumpsum consideration of Rs. 2,400 lakhs for which the consideration is received in the form of 9,140,342 equity shares and 101,193 Series 1 Preference Shares of Strand resulting in a gain of Rs. 614 lakhs.
- b During the year ended 31 March 2018, the Delhi unit of the Company became non-operational. Net charge on account of write off of receivables is Rs. 218 lakhs and the charge due to write off of net fixed assets is Rs. 546 lakhs. The total charge due to this unit closure is Rs. 764 lakhs.
- c During the year ended 31 March 2018, in accordance with the terms of share purchase agreement entered into with Regency Hospital Limited dated 28 March 2018, the Company sold its long-term investments in equity shares held in HCG Regency Oncology HealthCare Private Limited (HCG Regency) for a total consideration of Rs. 2,123 lakhs resulting in a gain of Rs. 444 lakhs. Pursuant to the above, HCG Regency has ceased to be subsidiary of the Company with effect from 29 March 2018. On account of a,b and c above, there is an exceptional gain of Rs.294 lakhs during the previous year ended 31 March 2018.
- 4 During the year ended 31 March 2018, HCG Pinnacle Oncology Private Limited, the wholly owned subsidiary of the Company ('Transferee Company'), has been merged with the Company ('Transferor Company') in accordance with the terms of a Scheme of Amalgamation approved by the Regional Director, Ministry of Corporate Affairs, Hyderabad dated 30 January 2018 ('the Scheme') with an appointed date of 1 April 2016. In line with Scheme and Ind AS 103, Business Combination requirement, the Company has considered the appointed date as 1 April 2016 and have considered the merger from the appointed date and accordingly have restated its results for the comparative quarters/periods including Earnings Per Share.

The impact of merger on the Statement are as follows:


Particulars	(Rs. in Lakhs)	
	for the quarter ended 31 December 2017	for the year to date period ended 31 December 2017
Total income	480	1,201
Total expenditure	578	1,437
Profit/ (loss) after tax	(70)	(150)
Basic earnings/(loss) per share	(0.08)	(0.17)
Diluted earnings/(loss) per share	(0.08)	(0.17)

- 5 During the year ended 31 March 2018, the Company had entered into a business transfer agreement with Dr.Gopichand ('Seller') dated 28 February 2018 for purchase of business undertaking owned and operated by the Seller in the name of City Cancer Centre ('CCC') located in Vijayawada. The Company has purchased the business on a slump sale basis for a sum consideration of Rs.5,200 lakhs payable partly by cash and partly by way of issuance of shares of the Company. Accordingly, Rs 1,500 lakhs was paid in cash during the year ended 31 March 2018, 934,500 equity shares of Rs. 10 at premium of Rs. 311 per share amounting to Rs 2,999 lakhs has been allotted to Dr. Gopichand during the quarter ended 30 June 2018 on preferential basis and the balance Rs 701 lakhs of contingent consideration will be paid on meeting the agreed performance condition.
- 6 During the period ended 31 December 2018, Apex Criticare LLP, holding 49.90% stake in one of the subsidiary of the Company, Apex HCG Oncology Hospitals LLP (Apex LLP) retired from Apex LLP and was paid an amount of Rs 2,525 lakhs as consideration. Pursuant to this, the Company along with its wholly owned subsidiary, Niruja Product Development and Healthcare Research Private Limited holds 100% interest in Apex LLP.
- 7 In accordance with the terms of the shareholders' agreement dated 22 March 2013 ('SHA') entered amongst the Company, BACC HealthCare Private Limited ('BACC') and the minority shareholder in BACC, the Company shall acquire the remaining 49.9% share capital of BACC from the minority shareholder as per the SHA. The consideration will be determined and settled as per the terms of the SHA, within the period as mutually agreed between the Company and the minority shareholder. On acquiring this stake, BACC would become a wholly owned subsidiary of the Company.
- 8 The Company has a single operating segment of 'setting up and managing hospitals and medical diagnostic services'.
- 9 Effective 1 April 2018 the Company has adopted Ind AS 115 - 'Revenue from Contracts with Customers' using the cumulative effect method. Accordingly, comparative periods were not restated. Based on the assessment, there is no material impact consequent to adoption of the standard.

For and on behalf of the Board of Directors

Dr. B. S. Ajjikumar
Chairman and CEO

Bengaluru, 7 February 2019



B S R & Co. LLP

Chartered Accountants

Maruthi Info-Tech Centre
11-12/1 Inner Ring Road
Koramangala
Bangalore 560 071 India

Telephone +91 80 7134 7000
Fax +91 80 7134 7999

Limited review report on unaudited quarterly consolidated financial results and consolidated year-to-date results of HealthCare Global Enterprises Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of HealthCare Global Enterprises Limited

We have reviewed the accompanying statement of unaudited consolidated financial results (“Statement”) of HealthCare Global Enterprises Limited (hereinafter referred to as “the Holding Company”), its subsidiaries (collectively referred to as ‘the Group’), its associate and its joint venture as listed in Annexure 1 for the quarter ended 31 December 2018 and the year-to-date results for the period from 1 April 2018 to 31 December 2018 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’).

This Statement is the responsibility of the Company’s Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these consolidated financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* specified under section 143(10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the consolidated financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We did not review the financial information of four subsidiaries and one step down subsidiary included in the statement of unaudited consolidated financial results and consolidated year-to-date financial results, whose unaudited financial information reflect total revenue (including other income) of Rs. 788 lakhs and Rs. 1,702 lakhs for the quarter ended 31 December 2018 and period from 1 April 2018 to 31 December 2018, respectively. The consolidated financial results also include the Group’s share of net loss (and other comprehensive income/expense) of Rs. 228 lakhs and Rs. 573 lakhs for the quarter ended 31 December 2018 and period from 1 April 2018 to 31 December 2018, respectively in respect of an associate and a joint venture whose financial information have not been reviewed by us. These unaudited financial information has been reviewed by other auditors whose reports have been furnished to us, and our opinion on the unaudited consolidated financial results and the year-to-date results, to the extent they have been derived from such unaudited financial information is based solely on the report of such other auditors

Our conclusion on the Statement is not modified with respect to the reports of the other auditors.

**Limited review report on unaudited quarterly consolidated financial results and consolidated year-to-date results of HealthCare Global Enterprises Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015
(continued)**

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

for B S R & Co. LLP

Chartered Accountants

Firm's Registration No: 101248W/W-100022



Amit Somani

Partner

Membership No. 060154

Place: Bengaluru

Date: 7 February 2019

HealthCare Global Enterprises Limited

Annexure 1: List of entities consolidated as at 31 December 2018

Sl. No.	Name of the Entity	Subsidiary/ Associate/ Joint Venture	Country of incorporation
1	BACC Healthcare Private Limited	Subsidiary	India
2	HCG Medi-Surge Hospitals Private Limited	Subsidiary	India
3	HCG Oncology LLP	Subsidiary	India
4	HealthCare Diwan Chand Imaging LLP	Subsidiary	India
5	HCG NCHRI Oncology LLP	Subsidiary	India
6	HCG EKO Oncology LLP	Subsidiary	India
7	APEX HCG Oncology Hospitals LLP	Subsidiary	India
8	HCG Manavata Oncology LLP	Subsidiary	India
9	Niruja Product Development & Healthcare Research Private Limited (formerly known as MIMS HCG Oncology Private Limited)	Subsidiary	India
10	HealthCare Global Senthil Multi Specialty Private Limited	Subsidiary	India
11	Malnad Hospital & Institute of Oncology Private Limited	Subsidiary	India
12	HCG Sun Hospitals LLP	Subsidiary	India
13	HCG (Mauritius) Private Limited	Step-down subsidiary	Mauritius
14	HealthCare Global (Africa) Private Limited Group (subsidiary till 30 June 2017)	Associate	Mauritius
15	Strand Life Sciences Private Limited (from 7 February 2018)	Joint Venture	India

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2018

(Rs. in Lakhs except share data)

Sl. No.	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the	Year to date	Year to date	Previous year
		31 December 2018	30 September 2018	months ended in the previous year 31 December 2017	figures for the current period ended 31 December 2018	figures for the previous period ended 31 December 2017	ended 31 March 2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	(a) Revenue from operations	24,820	24,474	20,626	71,892	60,843	82,879
	(b) Income from government grant	67	58	-	183	-	190
	(c) Other income	98	226	587	418	1,019	1,280
	Total income	24,985	24,758	21,213	72,493	61,862	84,349
2	Expenses						
	(a) Purchases of medical and non-medical items	5,558	5,829	4,978	16,466	15,080	19,664
	(b) Changes in inventories	101	(311)	(201)	(312)	(938)	(693)
	(c) Employee benefits expense	4,857	4,490	4,148	13,575	11,757	15,771
	(d) Finance costs	1,294	2,387	1,039	5,435	2,780	4,235
	(e) Depreciation and amortisation expense	2,193	2,063	1,824	6,229	5,018	7,146
	(f) Medical consultancy charges	5,676	5,107	4,660	15,578	13,306	17,422
	(g) Other expenses	5,801	6,067	4,434	17,469	12,974	19,023
	Total expenses	25,480	25,632	20,882	74,440	59,977	82,568
3	Profit/ (loss) before share of profit/(loss) of an associate / joint venture, exceptional items and tax (1-2)	(495)	(874)	331	(1,947)	1,885	1,781
4	Share of profit/(loss) of an associate / joint venture, net of taxes	(228)	(153)	19	(573)	(20)	(140)
5	Profit / (loss) before exceptional items and tax (3+4)	(723)	(1,027)	350	(2,520)	1,865	1,641
6	Exceptional items [refer note 3]	-	-	-	-	640	1,077
7	Profit/(loss) before tax (5+6)	(723)	(1,027)	350	(2,520)	2,505	2,718
8	Tax expense						
	- Current tax	8	84	339	216	855	1,355
	- Deferred tax	(128)	(347)	(109)	(736)	(60)	(331)
	Total tax expense	(120)	(263)	230	(520)	795	1,024
9	Profit / (loss) for the period / year (7-8)	(603)	(764)	120	(2,000)	1,710	1,694
10	Other comprehensive income / expense						
	(i) Items that will not be reclassified subsequently to profit or loss						
	- Remeasurements of the defined benefit plans	-	-	-	-	-	(25)
	- Exchange differences on translation of financial statements of foreign operations	(107)	209	-	102	-	-
	- Income tax effect on above	-	-	-	-	-	10
	(ii) Items that will be reclassified to profit or loss						
	- Effective portion of loss on hedging instruments in a cash flow hedge	(223)	(400)	29	(623)	-	-
	- Income tax on (ii) above	76	140	(10)	216	-	-
	Other comprehensive income /expense for the period / year, net of taxes	(254)	(51)	19	(305)	-	(15)
11	Total comprehensive loss for the period / year (9+10)	(857)	(815)	139	(2,305)	1,710	1,679
	Profit / (loss) for the period /year attributable to:						
	Equity holders of the Company	(620)	(647)	319	(1,608)	1,793	2,052
	Non-controlling interests	17	(117)	(199)	(392)	(83)	(358)
	Other comprehensive income / (loss) for the period / year attributable to						
	Equity holders of the Company	(254)	(51)	19	(305)	-	(18)
	Non-controlling interests	-	-	-	-	-	3
	Total comprehensive income / (loss) for the period / year attributable to						
	Equity holders of the Company	(874)	(698)	338	(1,913)	1,793	2,034
	Non-controlling interests	17	(117)	(199)	(392)	(83)	(355)
12	Paid-up equity share capital (Face value of Rs. 10 each)	8,789	8,786	8,688	8,789	8,688	8,690
13	Reserves, i.e., 'Other equity'						39,822
14	Earnings/(loss) per share (face value of Rs. 10 each)	Not annualised	Not annualised	Not annualised	Not annualised	Not annualised	Annualised
	(a) Basic	(0.71)	(0.74)	0.37	(1.83)	2.09	2.38
	(b) Diluted	(0.71)	(0.74)	0.37	(1.83)	2.09	2.38
	See accompanying notes to the Consolidated Financial Results						



STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2018

Notes:

1 The statement of unaudited consolidated financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company'), its subsidiaries (collectively referred to as 'the Group'), its associate and its joint venture, for the quarter and nine months ended 31 December 2018, has been reviewed by the Audit and Risk Management Committee and approved by the Board of Directors at their meeting held on 7 February 2019. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.

The Statement has been subjected to limited review by the statutory auditors of the Company. The review report of the auditor is unqualified.

2 The statement of category wise utilisation of net proceeds from Initial Public Offer is:

Category wise utilisation of net proceeds from Initial Public Offer	(Rs. in Lakhs)	
	Amount proposed to be utilised	Actual utilisation upto 31 December 2018
Purchase of medical equipment	4,220	-
Investment in IT software, services and hardware	3,019	1,627
Pre-payment of debt	14,704	14,700
General corporate purposes	1,977	1,977
Total	23,920	18,304

Details of unutilised funds as on 31 December 2018		(Rs. in Lakhs)
Investment in fixed deposits		1,077
Amount parked in cash credit account		4,539
Total		5,616

3 Exceptional items :

- During the period ended 31 December 2017, investment in HealthCare Global (Africa) Private Limited, is accounted under equity method as per Ind AS 28 'Investment in Associates and Joint Ventures' on account of change in control and the resultant gain of Rs. 640 lakhs is shown under exceptional items.
- During the year ended 31 March 2018, the Company has entered into a business transfer agreement with Strand Life Sciences Private Limited ('Strand') dated 2 January 2018 for sale of its Triesta unit on slump sale basis for a lumpsum consideration of Rs. 2,400 lakhs for which the consideration is received in the form of 9,140,342 equity shares and 101,193 Series 1 Preference Shares of Strand. Pursuant to the same, Strand has become an Associate of the Company effective 7 February 2018. The gain on slump-sale (after eliminating inter-company gain) is Rs. 380 lakhs.
- During the year ended 31 March 2018, the Delhi unit of the Company became non-operational. Net charge on account of write off of receivables is Rs. 218 lakhs and the charge due to write off of net fixed assets is Rs. 546 lakhs. The total charge due to this unit closure is Rs. 764 lakhs.
- During the year ended 31 March 2018, in accordance with the terms of share purchase agreement entered into with Regency Hospital Limited dated 28 March 2018, the Company sold its long-term investments in equity shares held in its subsidiary, HCG Regency Oncology Healthcare Private Limited ('HCG Regency') for a total consideration of Rs. 2,123 lakhs resulting in a gain of Rs.821 lakhs. Pursuant to the above, HCG Regency has ceased to be subsidiary of the Company with effect from 29 March 2018.

On account of a,b,c and d above, there is an exceptional gain of Rs. 640 lakhs for the period ended 31 December 2017 and Rs. 1,077 lakhs for the previous year ended 31 March 2018

- During the year ended 31 March 2018, the Company had entered into a business transfer agreement with Dr.Gopichand ('Seller') dated 28 February 2018 for purchase of business undertaking owned and operated by the Seller in the name of City Cancer Centre ('CCC') located in Vijayawada. The Company has purchased the business on a slump sale basis for a sum consideration of Rs 5,200 lakhs payable partly by cash and partly by way of issuance of shares of the Company. Accordingly, Rs 1,500 lakhs was paid in cash during the year ended 31 March 2018, 934,500 equity shares of Rs. 10 at premium of Rs. 311 per share amounting to Rs 2,999 lakhs has been allotted to Dr. Gopichand during the quarter ended 30 June 2018 on preferential basis and the balance Rs 701 lakhs of contingent consideration will be paid on meeting the agreed performance condition.
- During the period ended 31 December 2018, Apex Criticare LLP, holding 49.90% stake in one of the subsidiary of the Company, Apex HCG Oncology Hospitals LLP (Apex LLP) retired from Apex LLP and was paid an amount of Rs 2,525 lakhs as consideration. Pursuant to this, the Company along with its wholly owned subsidiary, Niruja Product Development and Healthcare Research Private Limited holds 100% interest in Apex LLP.
- In accordance with the terms of the shareholders' agreement dated 22 March 2013 ("SHA") entered amongst the Company, BACC HealthCare Private Limited ("BACC") and the minority shareholder in BACC, the Company shall acquire the remaining 49.9% share capital of BACC from the minority shareholder as per the SHA. The consideration will be determined and settled as per the terms of the SHA, within the period as mutually agreed between the Company and the minority shareholder. On acquiring this stake, BACC would become a wholly owned subsidiary of the Company.
- The Group has a single operating segment of 'setting up and managing hospitals and medical diagnostic services'.
- Effective 1 April 2018 the Group has adopted Ind AS 115 - 'Revenue from Contracts with Customers' using the cumulative effect method. Accordingly, comparative periods were not restated. Based on the assessment, there is no material impact consequent to adoption of the standard.

For and on behalf of the Board of Directors

Dr. B. S. Ajikumar
 Chairman and CEO



Bengaluru, 7 February 2019

